کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2144556 | 1088382 | 2006 | 7 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma](/preview/png/2144556.png)
SummaryPurposeTo evaluate the efficacy and tolerance of a cisplatin plus etoposide regimen followed by thoracic radiotherapy (TRT) and paclitaxel plus cisplatin consolidation chemotherapy in patients with limited stage small cell lung cancer (SCLC).Patients and methodsThirty-nine patients with limited SCLC were enrolled onto this study. Patients received three courses of cisplatin 75 mg/m2 IV, day 1 and etoposide 100 mg/m2 IV, days 1–3 (EP regimen), followed by TRT (45–56 Gy administered in 15 fractions), and three courses of paclitaxel 175 mg/m2 IV, day 1 and cisplatin, as previously, on day 2 (PP regimen); cycles were repeated every 21 days.ResultsAll patients were evaluable for toxicity and 34 for response. The overall response rate was 67% (CR: 26%; PR: 41%; intention-to-treat analysis) (95% CI: 53.0–84.2%). After a median follow-up period of 15 months, the median survival time was 15 months, the median time to tumor progression 8.3 months and the 1-year survival rate 53.8%. Grade 3/4 neutropenia occurred in 39% and 36% of patients receiving EP and PP regimens, respectively. The incidence of febrile neutropenia was 5% and 3% for EP and PP regimens, respectively. Other hematologic and non-hematologic toxicities were mild, with the exception of esophagitis occuring in 36% of patients during and/or immediately after radiotherapy.ConclusionConsolidation therapy with PP after sequential EP and thoracic radiotherapy is feasible and well-tolerated; however, the efficacy results are comparable with those previously obtained in the same patients’ population using a combination of EP and TRT.
Journal: Lung Cancer - Volume 53, Issue 1, July 2006, Pages 59–65